INTERNATIONAL PATENT: ZAI LAB (SHANGHAI) CO., LTD., ZAI LAB (US) LLC FILES APPLICATION FOR "DOSING REGIMENS OF ANTIBODY-DRUG CONJUGATE TARGETING DELTA-LIKE LIGAND 3 FOR TREATMENT OF NEUROENDOCRINE NEOPLASMS"

GENEVA, May 3 -- ZAI LAB (SHANGHAI) CO., LTD. (4560 Jinke Road, Building 1, 4/F, Shanghai Free Trade Zone, Pudong New AreaShanghai 201210), ZAI LAB (US) LLC (314 Main Street 4th Floor, Suite 100, CambridgeMA, 02142) filed a patent application (PCT/CN2024/126606) for "DOSING REGIMENS OF ANTIBODY-DRUG CONJUGATE TARGETING DELTA-LIKE LIGAND 3 FOR TREATMENT OF NEUROENDOCRINE NEOPLASMS" on Oct 23, 2024. With publication no. WO/2026/085745, the details related to the patent application was published on Apr 30, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): YE, Qiuping (C/o Zai Lab (US) LLC, 314 Ma...